smc evaluation project the view from industry
DESCRIPTION
SMC Evaluation Project The View From Industry. Martin Coombes Government Affairs Manager, AstraZeneca ABPI Representative SMC Evaluation Reference Group. “The Pharmaceutical Industry is recognised as a key partner by SMC and have supported the development of a robust and - PowerPoint PPT PresentationTRANSCRIPT
![Page 1: SMC Evaluation Project The View From Industry](https://reader035.vdocuments.mx/reader035/viewer/2022062519/5681500f550346895dbdf2a4/html5/thumbnails/1.jpg)
SMC Evaluation ProjectThe View From Industry
Martin CoombesGovernment Affairs Manager, AstraZeneca
ABPI Representative SMC Evaluation Reference Group
![Page 2: SMC Evaluation Project The View From Industry](https://reader035.vdocuments.mx/reader035/viewer/2022062519/5681500f550346895dbdf2a4/html5/thumbnails/2.jpg)
“The Pharmaceutical Industry is recognised as a key partner by SMC and have supported the development of a robust and transparent decision-making process.”
![Page 3: SMC Evaluation Project The View From Industry](https://reader035.vdocuments.mx/reader035/viewer/2022062519/5681500f550346895dbdf2a4/html5/thumbnails/3.jpg)
Life Science MessageScottish Medicines Consortium Work
![Page 4: SMC Evaluation Project The View From Industry](https://reader035.vdocuments.mx/reader035/viewer/2022062519/5681500f550346895dbdf2a4/html5/thumbnails/4.jpg)
SMC Evaluation Project
Management Group: Paul Catchpole
Reference Group: Martin Coombes, Jim Swift Andrew McGuigan
ABPI Scotland: Andy Powrie-Smith
SMC User Group Forum
![Page 5: SMC Evaluation Project The View From Industry](https://reader035.vdocuments.mx/reader035/viewer/2022062519/5681500f550346895dbdf2a4/html5/thumbnails/5.jpg)
SMC Evaluation Project
• Stakeholder engagement
• Medicines utilisation– Not recommended– Accepted for use/restricted use– SMC advice on unique treatment
• Evaluation of Budget Impact
![Page 6: SMC Evaluation Project The View From Industry](https://reader035.vdocuments.mx/reader035/viewer/2022062519/5681500f550346895dbdf2a4/html5/thumbnails/6.jpg)
Stakeholder Engagement• Evolving process• Industry seen as partner
– Continue to increase communication
• SMC process well recognised, timely, straightforward
• Consistent advice, but varying NHS Board processes and application, which would benefit from greater transparency
• Reduce duplication – NICE/AWMSG• More proactive patient involvement
![Page 7: SMC Evaluation Project The View From Industry](https://reader035.vdocuments.mx/reader035/viewer/2022062519/5681500f550346895dbdf2a4/html5/thumbnails/7.jpg)
Medicines Utilisation
![Page 8: SMC Evaluation Project The View From Industry](https://reader035.vdocuments.mx/reader035/viewer/2022062519/5681500f550346895dbdf2a4/html5/thumbnails/8.jpg)
![Page 9: SMC Evaluation Project The View From Industry](https://reader035.vdocuments.mx/reader035/viewer/2022062519/5681500f550346895dbdf2a4/html5/thumbnails/9.jpg)
Medicines Utilisation
• Not recommended
![Page 10: SMC Evaluation Project The View From Industry](https://reader035.vdocuments.mx/reader035/viewer/2022062519/5681500f550346895dbdf2a4/html5/thumbnails/10.jpg)
Medicines Utilisation
• Not recommended– 10 medicines remained not recommended
0.1% of the primary care spend 2005/6– Not added to formulary– No means No
![Page 11: SMC Evaluation Project The View From Industry](https://reader035.vdocuments.mx/reader035/viewer/2022062519/5681500f550346895dbdf2a4/html5/thumbnails/11.jpg)
Medicines Utilisation
• Not recommended– Delay of SMC advice– Limited use relative to alternative treatments– No alternative licensed products– Influence of pharmaceutical industry marketing strategy – Variation in advice issued by national bodies– Lack of engagement of relevant clinical experts in early
stages of SMC
![Page 12: SMC Evaluation Project The View From Industry](https://reader035.vdocuments.mx/reader035/viewer/2022062519/5681500f550346895dbdf2a4/html5/thumbnails/12.jpg)
Medicines Utilisation
• Accepted
![Page 13: SMC Evaluation Project The View From Industry](https://reader035.vdocuments.mx/reader035/viewer/2022062519/5681500f550346895dbdf2a4/html5/thumbnails/13.jpg)
Medicines Utilisation
• Accepted/Restricted Use– Data limitations– ‘Where alternative treatments already
exist, implementation of advice is subject to local NHS Board decision making’
– Acceptable variation?– Yes means Maybe
![Page 14: SMC Evaluation Project The View From Industry](https://reader035.vdocuments.mx/reader035/viewer/2022062519/5681500f550346895dbdf2a4/html5/thumbnails/14.jpg)
Unique Treatment
• Etanercept for psoriatic arthritis– HDL (2003) 60– No clean and relevant dataset– No single Scottish centre to collate data– Issues around local organisation structure
![Page 15: SMC Evaluation Project The View From Industry](https://reader035.vdocuments.mx/reader035/viewer/2022062519/5681500f550346895dbdf2a4/html5/thumbnails/15.jpg)
Budget Impact• Variable
– Actual vs Budget Impact• From +£3.2m to -£11.9m
– Multiple issues• Derivation unclear, Trial drop-out rates,
‘Restricted Use’, lack of uptake
– Compare actual uptake vs BI• Between NHS Boards• Other countries
Forward Look SMC Budget Impact
![Page 16: SMC Evaluation Project The View From Industry](https://reader035.vdocuments.mx/reader035/viewer/2022062519/5681500f550346895dbdf2a4/html5/thumbnails/16.jpg)
Key Conclusions
• Evolving and improving• Engagement
– More Pt group contact & Industry communication– Need greater understanding of local NHS Board processes
To provide consistency, transparency and accessibility
• Medicines Utilisation– Data? Variation in uptake?– When does yes mean yes?– Regular monitoring of uptake (compare with other countries)
• Budget Impact– Robust– Actual vs Budget Impact
![Page 17: SMC Evaluation Project The View From Industry](https://reader035.vdocuments.mx/reader035/viewer/2022062519/5681500f550346895dbdf2a4/html5/thumbnails/17.jpg)
R & D
![Page 18: SMC Evaluation Project The View From Industry](https://reader035.vdocuments.mx/reader035/viewer/2022062519/5681500f550346895dbdf2a4/html5/thumbnails/18.jpg)